胰腺癌患者采用吉西他滨联合白蛋白紫杉醇进行治疗的临床疗效研究
Clinical Efficacy Study of Pancreatic Cancer Patients Treated with Gemcitabine Combined with Albumin-Paclitaxel

目的：探讨胰腺癌患者采用吉西他滨联合白蛋白紫杉醇进行治疗的临床疗效。方法：回顾性分析2021年1月~2023年12月本院收入80例胰腺癌患者资料。按照治疗方式的不同分为对照组(n = 40)以吉西他滨单药治疗，试验组(n = 40)中以吉西他滨联合白蛋白紫杉醇治疗，比较两组实际治疗效果。结果：试验组总有效率与疾病控制率比对照组更高(P < 0.05)；两组患者治疗期间均未出现五级毒性反应，不良反应情况主要表现在肝功能异常、血小板计数减少、中性粒细胞分数减少、贫血、脱发等，不良反应分级多处于1/2级，3/4级者普遍较少，两组不良反应对比差异无统计学意义(P > 0.05)；治疗前，CA199、AFP、TSGF、CEA水平比较差异无统计学意义(P > 0.05)；治疗后，试验组血清肿瘤标志物CA199、AFP、TSGF、CEA水平均低于对照组，差异有统计学意义(P < 0.05)；试验组6个月以上存活率明显高于对照组，P < 0.05。结论：吉西他滨联合白蛋白紫杉醇治疗胰腺癌患者的耐受性良好，在减少不良反应发生的同时，延长患者的生存时间，临床治疗优势显著。
Objective: To investigate the clinical efficacy of gemcitabine combined with albumin-paclitaxel in patients with pancreatic cancer. Methods: Data of 80 pancreatic cancer patients from January 2021 to December 2023. According to the different treatment methods, the control group (n = 40) was treated with gemcitabine alone, and in the test group, gemcitabine (n = 40) was used to compare the actual treatment effect of the two groups. Results: In the test group, the total response rate and disease control rate were higher than those in the control group (P < 0.05); Neither group had grade V toxicity during treatment, The adverse reactions were mainly manifested in abnormal liver function, decreased platelet count, decreased neutrophil fraction, anemia, alopecia, etc., The grade of adverse reactions is mostly at level 1/2, Grade 3/4 were generally fewer, There was no significant difference between the adverse reactions of the two groups (P > 0.05); pretherapy, There was no significant difference in CA199, AFP, TSGF, and CEA levels (P > 0.05); post-treatment, The levels of serum tumor markers CA199, AFP, TSGF and CEA were lower than those in the control group, The difference was statistically significant (P < 0.05); The survival rate over 6 months in the test group was significantly higher than that in the control group, P < 0.05. Conclusion: Gemcitabine and albumin-paclitaxel are well tolerated in the treatment of pancreatic cancer patients, while reducing the occurrence of adverse effects, and prolonging the survival time of patients.